{"id":"W3030178583","doi":"10.1200/jco.20.00793","title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":759,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Lung cancer; Hazard ratio; Clinical endpoint; Etoposide; Population; Gastroenterology; Progression-free survival; Oncology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Chemotherapy; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005244841,0.0003981017,0.004814168,0.000168824,0.00021227,0.00004157502,0.0003386023,0.0003767558,0.0003357744],"category_scores_gemma":[0.008400469,0.0002399045,0.0007938126,0.0002404395,0.0005051063,0.0001443477,0.0002151027,0.001704337,0.000004875828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003914437,"about_ca_system_score_gemma":0.004925498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002406484,"about_ca_topic_score_gemma":0.0004038313,"domain_scores_codex":[0.9939471,0.0007725986,0.003413784,0.0005643825,0.0007266207,0.0005755172],"domain_scores_gemma":[0.9821501,0.01296061,0.00224054,0.0002803896,0.001362264,0.001006126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9657739,0.002918787,0.002063878,0.0003012373,0.003208347,0.001795316,0.002831375,0.000238183,0.00009315171,0.00001607648,0.006124298,0.01463545],"study_design_scores_gemma":[0.9113879,0.05873763,0.0002772695,0.0001510778,0.001726911,0.0001295383,0.001205454,0.00405791,0.0002398543,0.00003817889,0.02182004,0.0002282677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9363154,0.007962205,0.001186703,0.04455121,0.000930682,0.008206927,0.00002671983,0.00003300234,0.000787209],"genre_scores_gemma":[0.9619196,0.02362641,0.0009992059,0.007373358,0.003560575,0.0004813375,0.000005579063,0.00006988573,0.001964027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05581884,"threshold_uncertainty_score":0.9999522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2457992469628378,"score_gpt":0.5415262119285564,"score_spread":0.2957269649657187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}